default author photo

José R. Arribas

Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ

Campus Cantoblanco

C/Kelsen, 1

Madrid, Madrid 28049

Spain

SCHOLARLY PAPERS

8

DOWNLOADS
Rank 13,575

SSRN RANKINGS

Top 13,575

in Total Papers Downloads

8,701

TOTAL CITATIONS

16

Scholarly Papers (8)

1.

Reactogenicity and Immunogenicity of BNT162b2 in Subjects Having Received a First Dose of ChAdOx1s: Initial Results of a Randomised, Adaptive, Phase 2 Trial (CombiVacS)

Number of pages: 38 Posted: 27 May 2021
Hospital Universitario La Paz - Servicio de Farmacología Clínica, Hospital Universitario La Paz - Servicio de Farmacología Clínica, Instituto de Salud Carlos III- Laboratorio de Serología, University of the Basque Country - Biocruces Bizkaia Health Research Institute, Hospital Clinic of Barcelona - Preventive Medicine and Epidemiology Service, Carlos III Institute of Health - CIBER de Epidemiología y Salud Pública (CIBERESP), Hospital Vall d’Hebron - Servicio de Medicina Preventiva y Epidemiología, Instituto de Investigación Sanitaria San Carlos (IdISSC) - Servicio de Farmacología Clínica, Carlos III Institute of Health - National Centre for Microbiology, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, University of the Basque Country - Biocruces Bizkaia Health Research Institute, Hospital Clinic of Barcelona - Preventive Medicine and Epidemiology Service, Carlos III Institute of Health - Laboratorio de Serología, Institut de Recerca Hospital Universitari Vall d’Hebron (VHIR) - Unidad de Soporte a la Investigación Clínica, Universidad Complutense de Madrid (UCM) - Servicio de Farmacología Clínica, University Hospital 12 de Octubre, University of the Basque Country - Biocruces Bizkaia Health Research Institute, Hospital Clinic of Barcelona - Preventive Medicine and Epidemiology Service, Autonomous University of Barcelona - Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria San Carlos (IdISSC) - Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ, Carlos III Institute of Health - Laboratorio de Referencia en Inmunología, Carlos III Institute of Health - AIDS Immunopathogenesis Unit, Carlos III Institute of Health, Hospital Universitario La Paz - Servicio de Farmacología Clínica and Independent
Downloads 7,848 (2,106)
Citation 16

Abstract:

Loading...

Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS Study

Number of pages: 39 Posted: 21 Mar 2022
Carlos III Institute of Health - CIBER de Epidemiología y Salud Pública (CIBERESP), Carlos III Health Institute, affiliation not provided to SSRN, Hospital Universitario La Paz - Servicio de Farmacología Clínica, University of the Basque Country - Biocruces Bizkaia Health Research Institute, Hospital Clinic of Barcelona - Preventive Medicine and Epidemiology Service, Hospital Vall d’Hebron - Servicio de Medicina Preventiva y Epidemiología, Instituto de Investigación Sanitaria San Carlos (IdISSC) - Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Carlos III Institute of Health - National Centre for Microbiology, Carlos III Institute of Health - National Centre for Microbiology, Carlos III Institute of Health, Hospital Universitario La Paz - Servicio de Farmacología Clínica, University of the Basque Country - Biocruces Bizkaia Health Research Institute, affiliation not provided to SSRN, Institut de Recerca Hospital Universitari Vall d’Hebron (VHIR) - Unidad de Soporte a la Investigación Clínica, Universidad Complutense de Madrid (UCM) - Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Carlos III Institute of Health, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ, University of the Basque Country - Biocruces Bizkaia Health Research Institute, Hospital Clínic de Barcelona, Autonomous University of Barcelona - Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria San Carlos (IdISSC) - Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Icahn School of Medicine at Mount Sinai - Precision Immunology Institute, Carlos III Institute of Health, Hospital Universitario La Paz - Servicio de Farmacología Clínica, Instituto de Salud Carlos III- Laboratorio de Serología, Carlos III Institute of Health - AIDS Immunopathogenesis Unit and Independent
Downloads 76 (840,816)

Abstract:

Loading...

SARS-CoV-2, heterologous vaccination, Neutralisation, Variants, antibodies

3.

Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial

Number of pages: 34 Posted: 03 Aug 2022
University of Oslo - Section for Clinical Immunology and Infectious Diseases, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, University of Oslo - Institute of Clinical Medicine, University of Lille, affiliation not provided to SSRN, University of Verona, Hospital Universitario Virgen Macarena - Unidad Clínica de Enfermedades Infecciosas, affiliation not provided to SSRN, Université Libre de Bruxelles (ULB), Medical University of Innsbruck, Government of Portugal - Unidade Local de Saúde de São João, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Division of Emergencies and Critical Care, University of Claude Bernard Lyon 1, affiliation not provided to SSRN, University of Pécs, National and Kapodistrian University of Athens, University Hospital Brno, University of Basel - University Hospital Basel, Hacettepe University, Technische Universität München (TUM), Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Oslo University Hospital, affiliation not provided to SSRN, Vestre Viken Hospital Trust, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, University of Oslo - Institute of Clinical Medicine, University of Stavanger - Stavanger University Hospital, Hospital Universitario La Paz, Vestre Viken Hospital Trust, University Hospital North Norway, Hospices Civils de Lyon - Service de Médecine Intensive-Réanimation, Akershus University Hospital - Department of Infectious Diseases, Norwegian Institute of Public Health, Sorbonne University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Department of Immunology and Transfusion Medicine, Hospices Civils de Lyon - Laboratoire de Virologie, University of Nantes - INSERM, University of Oslo - Oslo University Hospital, Norwegian Institute of Public Health, University of Verona - Infectious Diseases, Department of Diagnostic and Public Health, affiliation not provided to SSRN, University of Oslo - Department of Research Support for Clinical Trials and Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP
Downloads 176 (428,796)

Abstract:

Loading...

COVID-19, immunomodulator, safety, baricitinib, JAK inhibitor

4.

Effects of Jak Inhibitors in Adults Hospitalized Due to Covid-19: A Systematic Review and Individual Participant Data Meta-Analysis of Randomized Clinical Trials

Number of pages: 27 Posted: 03 Oct 2024
Basel University - CLEAR Methods Center, University of Basel - University Hospital Basel, University of Basel, University of Basel - University Hospital Basel, Basel University - CLEAR Methods Center, University of Basel - University Hospital Basel, Basel University - CLEAR Methods Center, University Hospitals of Geneva, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), The Emmes Company, Hospital Universitario de Fuenlabrada, Hospital Universitario de Fuenlabrada, Ospedali Riuniti di Ancona, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Mazandaran University of Medical Sciences, University of Cambridge, NHS Foundation Trust - Cambridge University Hospitals, Hospital Universitario La Paz, Hospital Universitario La Paz, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ, Hospital Israelita Albert Einstein, Hospital Israelita Albert Einstein, University of Sydney - George Institute for Global Health, Hôpital Bichat - Claude-Bernard - INSERM, IAME Infectious Diseases Department, Norwegian Institute of Public Health, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Université Libre de Bruxelles (ULB) - Department of Infectious Disease, Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, University of Verona - Infectious Diseases, Department of Diagnostic and Public Health, Hôpital Bichat, APHP, Université Paris Cité, Université Paris Cité, Université Paris Cité, University of Nantes - INSERM, Sorbonne University, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Section for Clinical Immunology and Infectious Diseases and University of Basel - University Hospital Basel
Downloads 174 (437,795)

Abstract:

Loading...

5.

The CONSENSUS-LAI Study: Establishing Shared Definitions of Virological Failure and Discontinuation for Long-Acting Injectable Cabotegravir and Rilpivirine Therapy

Number of pages: 27 Posted: 10 Jan 2025
Barts Health NHS Trust, University of Oxford, Queen Mary University of London, Queen Mary University of London, Imperial College London - Department of Infectious Disease, Independent, University of Geneva - Geneva University Hospitals, University of Rome Tor Vergata, University of Chicago, NYU Grossman - School of Medicine, Emory University - Division of Infectious Diseases, University of Angers - French Institute of Health and Medical Research (INSERM), Imperial College London - Department of Paedaitric Infectious Diseases, University of Alabama at Birmingham, Emory University - Division of Infectious Diseases, University of Chile - Faculty of Medicine, Università degli studi di Modena e Reggio Emilia (UNIMORE) - Clinic of Infectious Diseases, Harvard University - Harvard Medical School, University of Toronto - Saint Michael's Hospital, Universidad de Barcelona - Hospital Clínic Barcelona, University of Amsterdam - Department of Internal Medicine, University of Sussex - Brighton and Sussex Medical School, University of the Witwatersrand - Faculty of Health Sciences, Chaim Sheba Medical Center - Infectious Diseases Unit, Columbia University - Division of Infectious Diseases, University of Paris - INSERM U944, Monash University - Department of Infectious Diseases, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ, Hospital Universitari Germans Trias i Pujol - Infectious Diseases Department, University of California, Los Angeles (UCLA), University of Bonn - Department of Internal Medicine I, Helsinki University Hospital, Johns Hopkins University, University College London, University of Gothenburg - Sahlgrenska University Hospital, East Sydney Doctors, Government of the United Kingdom - Department of HIV/GUM, Thacker & Thompson MD, Pomeranian Medical University, The University of Western Australia - Royal Perth Hospital, University of California, San Francisco (UCSF) - Division of HIV, Infectious Diseases and Global Medicine, Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), National University of Singapore (NUS), Imperial College London - Imperial College Healthcare NHS Trust, Fundación Huésped, George Washington University, MVZ München am Goetheplatz, University of Toronto - University Health Network, HIV i-Base, Global Network of People Living with HIV/AIDS (GNP+), Queen Mary University of London, University of Pennsylvania - Hospital of the University of Pennsylvania, University Hospitals Sussex NHS Foundation Trust and Queen Mary University of London - Wolfson Institute of Population Health
Downloads 169 (444,808)

Abstract:

Loading...

HIV, Antiretroviral Therapy, Cabotegravir, Rilpivirine, Long-Acting Injectable Therapy, Virological Failure, Viral Load, Drug Resistance, Treatment Discontinuation, Treatment Outcome, Consensus, Delphi Technique

6.

Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons with Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicentre, Phase IIa Clinical Trial

Number of pages: 28 Posted: 09 Oct 2024
Hospital Universitario La Paz, Hospital Universitario Doce de Octubre, University of Barcelona - Infectious Disease Department, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Hospital Universitario La Paz, Instituto de Investigación Sanitaria Princesa - Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Autonomous University of Barcelona - Hospital del Mar, University of Barcelona - Department of Infectious Diseases, Hospital Universitario La Paz, Bellvitge University Hospital, University of Alcala - Hospital Universitario Príncipe de Asturias, Instituto de Investigacion Biomédica de Cádiz (INiBICA) - Unidad de Enfermedades Infecciosas, SEIMC-GESIDA Foundation, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ and Independent
Downloads 98 (699,467)

Abstract:

Loading...

Dolutegravir, lamivudine, resistance, proviral DNA, M184V

7.

Effect of a COVID-19-Heterologous Vaccination Schedule on Haemostasis: A Subanalysis of the Phase 2, Multicentre, Randomised, Controlled CombiVacS Study

Number of pages: 27 Posted: 01 Mar 2022
Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz - Department of Laboratory Medicine, Hospital Universitario La Paz, Carlos III Institute of Health, Hospital Universitario La Paz - Servicio de Farmacología Clínica, Hospital Universitario La Paz - Servicio de Farmacología Clínica, Hospital Universitario La Paz, Hospital Universitario La Paz, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Hospital Universitario La Paz - Servicio de Farmacología Clínica, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ and Hospital Universitario La Paz
Downloads 88 (753,595)

Abstract:

Loading...

COVID-1, heterologous vaccination, haemostasis

8.

Partial Recovery of Telomere Length after Long-Term Virological Suppression in Persons Living with HIV

Number of pages: 14 Posted: 26 Jun 2024
Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Hospital Universitario La Paz and Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ
Downloads 72 (860,052)

Abstract:

Loading...

HIV, Telomere, Aging